FORM reported Q2 results on July 29 — and the setup has now shifted from pre-earnings anxiety to post-earnings reckoning, with the stock down 22% on the week after a beat that clearly wasn't enough for a market already pricing in something worse.
The numbers themselves were not the problem. Q2 revenue came in at $243.5M, beating estimates by 4.5%, and management raised full-year guidance. Yet the stock closed at $88.23 on July 28, having shed more than 10% in a single session and nearly a third of its value over the past month. That kind of reaction to an apparent beat points to a guidance read or margin commentary that disappointed investors more than the headline revenue figure reassured them. The selloff is broad rather than isolated: close peers ONTO fell 19% on the week, MKSI dropped 17%, and AMKR was the worst of the group at down 31%. This is a sector-wide compression, not a FORM-specific disaster — though FORM is underperforming most of the cohort on a one-month basis after its earlier slide.
Positioning reflects genuine nervousness that predated the print and has not unwound. The put/call ratio hit 1.13 on July 28 — the highest reading of the past 52 weeks, running 1.8 standard deviations above its 20-day average of 0.72. That protective hedging demand was already the story heading into results; the question now is whether it persists or unwinds as investors reassess. Short interest tells a building but not alarming story: it rose 34% in the past week to 3.7% of the free float, with the bulk of that jump concentrated in the July 23-24 window. Borrowing costs remain low at 0.48%, and availability is extraordinarily loose at around 6,500% — meaning shares available to borrow vastly outnumber those already borrowed. There is no squeeze dynamic here, and no sign the lending market is tightening in response to the selloff.
The Street entered earnings in a broadly constructive but conflicted posture. Analyst data is now more than six weeks old relative to today's print, so the picture reflects pre-earnings positioning rather than post-results reaction — note that some targets cited below will likely be revised sharply in coming days. As of mid-June, the consensus was a split five-buy, five-hold, with price targets clustered between $150 and $175. At $88, the stock is trading at roughly half the mean target — a gap that either reflects how stale those targets now are or signals that the market has moved far faster than the Street. The bull case rests on consistent gross margin improvement, AI-driven wafer test demand, and the Texas production ramp. The bear case centres on tariff headwinds, margin expansion slowing, and revenue concentration risk. The valuation has compressed sharply: the price-to-earnings multiple fell nearly 22 points over the past month to 33x, and the price-to-book ratio dropped 3.5 points. The ORTEX short score of 33 is low, suggesting the data-driven signal on short pressure remains contained despite the price damage.
The one mildly eyebrow-raising data point in the ownership picture is CEO Mike Slessor's cluster of sales on July 15 — a total of roughly 4,700 shares at prices between $116 and $121, worth just under $560,000 in aggregate. The significance scores are low (rated 2 out of 10), and the trades look routine relative to his position size. The chairman also sold 2,800 shares in June at $151. Neither transaction is alarming in isolation, but the timing — well above where the stock now trades — adds a layer of context to how quickly the narrative has shifted.
What to watch now is whether analyst price-target revisions in the days following the print pull the consensus sharply lower, and whether the options market's elevated put/call ratio begins to normalise as the earnings overhang clears — or stays elevated if guidance interpretation remains contested.
See the live data behind this article on ORTEX.
Open FORM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
